{"id":"W4402135000","doi":"10.1093/eurheartj/ehae614","title":"Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial","year":2024,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Canadian VIGOUR Centre; Alberta Hospital Edmonton; Health Sciences Centre; University Health Network; St. Michael's Hospital","funders":"American Regent; Genentech; U.S. Food and Drug Administration; Sanofi Australia; MicroPort; Idorsia Pharmaceuticals; Novo Nordisk; Akebia Therapeutics; Bristol-Myers Squibb; Cleveland Clinic; CryoLife; Janssen Scientific Affairs; AstraZeneca; Amarin Corporation; XBiotech; ReCor Medical; Intarcia Therapeutics; National Institutes of Health; Regeneron Pharmaceuticals; Boston Scientific Corporation; Daiichi Sankyo Europe; Servier; Gilead Sciences; Duke Clinical Research Institute; FibroGen; Esperion Therapeutics; Alnylam Pharmaceuticals; Kowa Company; Sanofi; HLS Therapeutics; Conselho Nacional de Desenvolvimento Científico e Tecnológico; GlaxoSmithKline; Amgen; York University; Moderna; Pfizer; CSL Behring; Jewish General Hospital; Bayer Corporation; Daiichi-Sankyo; AtriCure; Eli Lilly and Company","keywords":"Medicine; Myocardial infarction; Ldl cholesterol; Internal medicine; Apolipoprotein B; Cholesterol; Cardiology; Baseline (sea)","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008009381,0.000291586,0.0007524042,0.0004394888,0.0005343558,0.0003045371,0.0001554255,0.0000775673,0.00003645055],"category_scores_gemma":[0.0004742386,0.0001872649,0.0009834577,0.0004983143,0.00005919575,0.0002423069,0.0002678959,0.001264029,0.00008086894],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000137222,"about_ca_system_score_gemma":0.0002368381,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002087391,"about_ca_topic_score_gemma":0.00001784918,"domain_scores_codex":[0.996212,0.001227382,0.0006425499,0.0004539796,0.0009529289,0.0005111286],"domain_scores_gemma":[0.9985928,0.00009317532,0.00005157219,0.0007133032,0.00009893532,0.0004502362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007282775,0.0004974483,0.03786519,0.0003477671,0.01178761,0.00436212,0.006778336,0.0009974957,0.006890249,0.0001610867,0.01369985,0.9093301],"study_design_scores_gemma":[0.02773593,0.002035759,0.4204925,0.001077801,0.001353526,0.01042251,0.0009387666,0.0003634007,0.0001770027,0.00004775076,0.5348045,0.0005505118],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9780537,0.003022086,0.001923151,0.01275554,0.00176801,0.001651231,0.00001598904,0.00009643593,0.0007138396],"genre_scores_gemma":[0.9911432,0.0005884204,0.0006105109,0.002618354,0.004560601,0.00003796482,0.000004276885,0.00008888458,0.0003478386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9087796,"threshold_uncertainty_score":0.7636442,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04734247871768454,"score_gpt":0.3188666813549959,"score_spread":0.2715242026373113,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}